Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM EBIT per Share is $0.06 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, NovelStem International ranks better than 70.12% on this metric.
NovelStem International's EBIT per Share for the
three
months ended in Mar. 2026 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.
During the past 3 years, the average EBIT per Share Growth Rate was 32.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 40.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 35.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NovelStem International's EBIT per Share or its related term are showing as below:
NSTM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.1 Med: 7.5 Max: 64.6
Current: 32.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NovelStem International was 64.60% per year. The lowest was -60.10% per year. And the median was 7.50% per year.
NSTM's 3-Year EBIT Growth Rate is ranked better than 70.12% of 164
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs NSTM: 32.10
NovelStem International (OTCPK:NSTM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NovelStem International EBIT per Share Related Terms
NovelStem International EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International (NSTM) has a EBIT per Share of $0.06 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #49 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 29.9%.
Is NovelStem International's EBIT per Share too high?
NovelStem International's current EBIT per Share is $0.06. The Medical Diagnostics & Research industry median EBIT per Share is 13.10. NovelStem International's value of $0.06 is 99.5% below this industry median. Based on the distribution chart, NovelStem International ranks #49 out of 164 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does NovelStem International's EBIT per Share compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #49 out of 164 companies for EBIT per Share. This puts NovelStem International in the upper half of its industry. The industry median EBIT per Share is 13.10. NovelStem International's value of $0.06 is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovelStem International's current EBIT per Share of $0.06 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NovelStem International and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current EBIT per Share is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current EBIT per Share of $0.06. The current EBIT per Share is $0.06 and 99.5% below the Medical Diagnostics & Research industry median of 13.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NovelStem International (NSTM), the current EBIT per Share is $0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
